contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


issue-and-re-purchase-of-class-c-shares-for-incentive-program-3

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Biotage är verksamt inom bioteknik. Bolaget tillhandahåller lösningar inom kromatografi, organisk syntes och provberedning. Bolaget har verksamhet på global nivå, främst koncentrerat till Europa, Nordamerika och Asien och en stor del av projekten bedrivs även i samarbete med övriga aktörer inom nämnd marknad. Kunderna återfinns inom vård och omsorg, samt inom livsmedelsindustrin.

Biotage

The Board of Directors of Biotage AB (publ) (“Biotage”) has today resolved, by virtue of the authorisation by the Annual General Meeting held on April 25, 2024, to issue and immediately thereafter...

<div class="mfn-preamble"><p><strong>The Board of Directors of Biotage AB (publ) (“Biotage”) has today resolved, by virtue of the authorisation by the Annual General Meeting held on April 25, 2024, to issue and immediately thereafter re-purchase 286,440 class C shares. The shares are issued and re-purchased in accordance with the incentive program LTIP 2024 which was adopted by the Annual General Meeting held on April 25, 2024.</strong></p></div><div class="mfn-body"><p>Danske Bank A/S, Danmark, Sverige Filial, will subscribe for the entire issue of new class C shares at a subscription price of SEK 1.39 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors’ resolution, be re-purchased by Biotage for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2024.</p><p>The purpose of the re-purchase is to ensure delivery of shares to participants and to secure social contributions arising as a result of LTIP 2024. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.</p></div><div class="mfn-footer mfn-e7343beb9afa"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Torben Jörgensen, Interim President &amp; CEO <br>Tel: +46-707 49 05 84, <a rel="noopener" href="mailto:torben.jorgensen@biotage.com">torben.jorgensen@biotage.com</a></p></div><div class="mfn-footer mfn-about mfn-0a7046178eae"><p><strong class="mfn-heading-1">About Biotage</strong></p><hr><p>Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers’ workflows and improving their outcomes. </p><p>Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).<br>Website: <a rel="noopener" href="https://www.biotage.com">www.biotage.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/d9c7cd9f-c787-4970-a78e-609127539b7a/issue-and-re-purchase-of-class-c-shares-for-incentive-program.pdf" class="mfn-generated mfn-primary">Issue and re-purchase of class C shares for incentive program</a></p></div>

Issue and re-purchase of class C shares for incentive program

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Beställ vårt nyhetsbrev — inget användarkonto krävs!